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Despite 20 years of research, a vaccine to prevent hepatitis C virus (HCV) infection has not
been developed. A vaccine to prevent HCV will need to induce broadly reactive immunity
able to prevent infection by the 7 genetically and antigenically distinct genotypes circulating
world-wide. HCV encodes two surface exposed glycoproteins, E1 and E2 that function as
a heterodimer to mediate viral entry. Neutralizing antibodies (NAbs) to both E1 and E2 have
been describedwith themajor NAb target being E2.The function of E2 is to attach virions to
host cells via cell surface receptors that include, but is not limited to, the tetraspanin CD81
and scavenger receptor class B type 1. However, E2 has developed a number of immune
evasion strategies to limit the effectiveness of the NAb response and possibly limit the
ability of the immune system to generate potent NAbs in natural infection. Hypervariable
regions that shield the underlying core domain, subdominant neutralization epitopes and
glycan shielding combine to make E2 a difﬁcult target for the immune system.This review
summarizes recent information on the role of NAbs to prevent HCV infection, the targets of
theNAb response and structural information on glycoprotein E2 in complexwith neutralizing
antibodies.This new information should provide a framework for the rational design of new
vaccine candidates that elicit highly potent broadly reactive NAbs to prevent HCV infection.
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ARTICLE
The most cost effective means of controlling infectious disease is
through vaccination, however, a prophylactic or therapeutic vac-
cine for HCV is not available. HCV is a small, enveloped positive
sense RNA virus within the Flaviviridae family. HCV is classiﬁed
into seven major genotypes that display up to 33 % nucleotide
variation and >100 subtypes that display up to 20% nucleotide
variation. The genotypes of HCV have a geographical distribution
with genotypes 1–3 prevalent world-wide. Individuals infected
with HCV harbor a swarm of closely related viruses referred to as
a quasispecies. The degree of sequence variation observed forHCV
exceeds that for HIV and inﬂuenza, posing a major challenge to
vaccine development. Essential to the success of an HCV vaccine
will be an ability to confer broad protection against the circulating
strains of HCV.
THE ROLE OF ANTIBODY IN HCV INFECTION
The effectiveness of all current licensed viral vaccines relies on the
production of neutralizing antibody (NAb; Lambert et al., 2005).
Strong evidence now exists that NAbs play a major role in clear-
ance of HCV infections. Longitudinal analysis of HCV infection
cohorts reveals that broadly speciﬁc NAb (brNAb) elicited early
in infection correlates with viral clearance (Lavillette et al., 2005;
Pestka et al., 2007; Dowd et al., 2009). By contrast, people who
failed to make NAbs progressed to chronic infection. Sequence
analysis of the structural region during chronic infection reveals
that the development of a NAb response correlates with sequence
evolution, likely to be a result of immune escape (von Hahn et al.,
2007; Liu et al., 2010). In a single case study, Raghuraman et al.
(2012) examined the NAb and cellular immune responses in a
patient with long term chronic HCV who spontaneously cleared
their virus after 62 weeks of infection. Viral clearance correlated
with the appearance of NAb at 48 weeks and a reversal of T cell
exhaustion. Neutralizing antibodies also play an important role
in people who have previously cleared their HCV infection but
become infected on reexposure to HCV. Neutralizing antibodies
were detected during the acute phase of infection in 60% of rein-
fected participants who went on to clear their reinfection but was
not detected in 2 patients who progressed to chronic infection
(Osburn et al., 2010). Overall, the ﬁndings of these studies suggest
that the development of a NAb response during the early phase of
acute infection is a strong correlate of viral clearance. Consistent
with these observations, passive transfer of broadly neutralizing
monoclonal or polyclonal NAbs to experimental animals protects
them against viral challenge (Law et al., 2008; Vanwolleghem et al.,
2008; Morin et al., 2012). However, administration of a sterilizing
dose of antibody must precede infection, otherwise the antibody
is not effective at preventing infection, but can reduce viral loads
(Meuleman et al., 2008; Morin et al., 2012).
HCV GLYCOPROTEINS E1 AND E2
Hepatitis C virus encodes two glycoproteins, E1, and E2 that are
cleaved from the viral polyprotein by signal peptidases. E1/E2
function as a heterodimer to mediate viral entry. E2 mediates
attachment to cellular receptors CD81 and scavenger receptor
class B type 1 (SR-B1) via sequences within its RBD (Pileri et al.,
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1998; Scarselli et al., 2002). The functional properties of E1/E2 and
the ability of E1/E2-speciﬁc antibodies to prevent viral entry can
be studied using retroviruses pseudotyped with E1/E2 (HCVpp;
Bartosch et al., 2003; Drummer et al., 2003; Hsu et al., 2003) or cell
culture derived HCV (HCVcc) made by transfecting full-length
HCV RNA into Huh 7 cells (Lindenbach et al., 2005; Wakita et al.,
2005; Yi et al., 2006).
Glycoprotein E1 is essential for viral entry as HCVpp lacking E1
is non-infectious but its function in entry is unknown (Drummer
et al., 2003). E1 contains a C-terminal transmembrane domain
(TMD) that anchors the ectodomain to the virion and contains
four or ﬁve glycosylation sites (Figure 1A). Relatively few NAbs
have been described for E1 (Keck et al., 2004b;Meunier et al., 2008)
suggesting it is a subdominant immunogen in natural infection.
GlycoproteinE1 is essential for the correct assembly and stability of
the E1/E2 heterodimer in HCVcc and allosterically modulates the
structure of E2 and its ability to bind cellular receptors (McCaffrey
et al., 2011; Wahid et al., 2013).
Glycoprotein E2 comprises ∼ 11 largely conserved N-linked
glycosylation sites and 18 conserved cysteines (Figure 1A). The
receptor binding domain, residues 384–661 (RBD), folds inde-
pendently of other E1/E2 sequences. The RBD is linked through
a conserved C-terminal stem to the TMD (Drummer and Poum-
bourios, 2004; Figure 1A). The binding site for CD81, the major
cellular receptor for all HCV strains, comprises highly conserved
segments within the E2 RBD (Drummer et al., 2002; Roccasecca
et al., 2003; Zhang et al., 2004; Drummer et al., 2006; Owsianka
et al., 2006; Figure 1A). These regions of E2 interact with the
large extracellular loop (LEL) of CD81 through Ile182, Asn184,
Phe186, and Leu162 on the head subdomain (Higginbottom et al.,
2000; Drummer et al., 2002).
VARIABLE REGIONS OF THE E2 GLYCOPROTEIN
Locatedwithin the RBD are four variable regions (Figure 1A). The
N-terminal hypervariable region 1 (HVR1) is 27 amino acids in
length and resides outside the core domain of E2, and no structural
information is available (Weiner et al., 1991; Kato et al., 1992).
Despite the high degree of sequence variation, the overall basic
charge of this region is preserved, possibly to maintain interac-
tions with SR-B1 (Penin et al., 2001; Dao Thi et al., 2011). Deletion
of HVR1 from the E2 RBD abolishes the interaction with SR-B1,
while deletion of HVR1 in the context of HCVpp abolishes high-
density lipoprotein (HDL)-mediated enhancement of viral entry,
thereby increasing the effectiveness of NAb (Dao Thi et al., 2011).
Originally, hypervariable region 2, HVR2, was described as a nine
amino acid sequence (Kato et al., 1992) downstream of HVR1.
Further analysis across different HCV genotypes suggested a more
extensive area of variation (res. 461–481) ﬂankedby conserved cys-
teine residues that form a surface exposed disulﬁde bonded loop,
not essential for folding of the E2RBD core (McCaffrey et al., 2007;
Kong et al., 2013). Sequence identity within HVR2 ranges from
39% in genotypes 1a and b to 93% in genotype 5a (McCaffrey et al.,
2007). An additional cysteine-ﬂanked variable region (igVR, res.
570–580) was described that is relatively conserved within a geno-
type but exhibits a high degree of intergenotypic variation in both
length (10–15 res) and sequence (McCaffrey et al., 2007). Deletion
of either HVR2 or the igVR in the context of E1/E2 incorporated
into HCVpp is not tolerated as E2 fails to form heterodimers with
E1 and the resultant HCVpp are not infectious (McCaffrey et al.,
2011). These data suggest that HVR2 and the igVR are essential to
the virion incorporated E1/E2 structure. There is no evidence in
the literature to suggest that HVR2 or the igVR are targets of the
antibody response and so are unlikely to be under immune pres-
sure. McCaffrey et al. (2007) have shown that HVR1, HVR2, and
the igVR can be simultaneously deleted from the RBDwithout dis-
rupting its native fold and receptor binding ability, indicating that
they are outside a conserved core domain (McCaffrey et al., 2007).
Analysis of sequence variation within patient isolates revealed a
third hypervariable region (HVR3) within the sequence 434–450,
that appears to be under immune selection pressure (Troesch et al.,
2006; Torres-Puente et al., 2008).
THE THREE DIMENSIONAL STRUCTURE OF THE E2 CORE
DOMAIN
Recently, X-ray crystallography and electronmicroscopy have pro-
vided the ﬁrst insights into the structure of glycoprotein E2. The
structure provided by Kong et al. (2013) was obtained for an E2
core domain containing residues 412–645 that lacked two glyco-
sylation sites at Asn448 and Asn576, and HVR2 residues 460–485
were replaced with a Gly-Ser-Ser-Gly linker (Figure 1B). The sec-
ond structure was for an E2 core comprising residues 456–656
(Khan et al., 2014). The structureswere largely similar and revealed
that unlike its related glycoprotein E ﬂavivirus counterparts HCV
E2 does not have a three domain architecture reminiscent of other
class II fusion proteins. Instead, E2 core adopts a compact globu-
lar immunoglobulin-like fold comprising a central β-sandwich
surrounded by short front and back layers comprising loops,
short helices and β sheets (Kong et al., 2013; Khan et al., 2014;
Figures 1B,C). Veriﬁcation that E2 adopts a compact globular
fold when expressed as the complete E2 ectodomain was provided
by electron microscopy (Kong et al., 2013). The immunoglobu-
lin fold resembles domain III of the class II fusion proteins, the
only common structural element with the alpha and ﬂavivirus
fusion proteins. In the core domain of HCV E2, 8 disulﬁde bonds
were formed but many regions lacked regular secondary struc-
ture including the regions between residues 412–420 and 454–491
surrounding the truncated HVR2 region and a loop at 586–596
(Kong et al., 2013). Six of the N-linked glycans also were also
largely disordered at Asn417, Asn423, Asn532, Asn540, Asn623,
and Asn556 (Kong et al., 2013). The immunoglobulin sandwich is
formed by 4 β strands that form an inner sheet and two solvent
exposed β strands that comprise the outer sheet. A loop con-
nects the inner sheet to the outer sheet and contains many of
the key CD81 binding residues and is adjacent to the front layer
where additional CD81 contact residues are found that are surface
exposed (Figures 1D,E). The igVR is within a ﬂexible region span-
ning 567–596 and the back layer is formed by two short α-helices
and 4 β sheets.
TARGETS OF THE ANTIBODY RESPONSE TO HCV
ANTIBODY RESPONSE TO E1
Neutralizing monoclonal antibodies speciﬁc to E1 or epitopes that
are targets of NAbs have beendescribed although they are relatively
limited in number. This may in part be due to the inability to
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FIGURE 1 | (A) Schematic of hepatitis C virus glycoproteins E1 and E2
showing the location of conserved glycosylation sites (trees). The
transmembrane domains are shown in black and the E2 stem region is
indicated with a cylinder. The location of hypervariable regions in E2 is
shown in red and the three immunogenic epitopes designated epitopes
I, II, and III are underlined. Regions involved in CD81 binding are
shown in green with speciﬁc contact residues shown in Table 1.
(B) Schematic of the E2 core domain according to the designations of
Kong et al. (2013). (C) Structure of the E2 core domain colored
according to B. (D) Surface representation of C. Purple and teal
regions represent the neutralizing face of E2 and overlap with CD81
contact residues shown in E. (E) Surface representation of the E2 core
domain with those residues involved in CD81 with their locations
colored according to B.
express a recombinant form of E1 that is a known mimic for the
structure of E1 in virions and the likelihood that E1 is largely
occluded by E2 in virion incorporated heterodimers. Antibody H-
111 binds an epitope at theN-terminus of E1, immunoprecipitates
E1/E2 heterodimers and has cross-neutralizing potential (Keck
et al., 2004b). Two MAbs isolated from a human who had cleared
their genotype 1b infection, IGH505 and IGH526 recognize over-
lapping but distinct epitopes within the sequence 307–340, and
neutralize genotypes 1a, 1b, 4a, 5a, and 6a viruses, but not 2b or
3a. Interestingly, only 2/31 MAbs isolated by Meunier et al. (2008)
were speciﬁc to E1 neutralized virus suggesting that such anti-
bodies may be rarely elicited. Additional epitopes recognized by
human serum have been discovered using overlapping peptides or
usingmass spectrometry and include epitopes at 264–318 (Kachko
et al., 2011) and 308–325 (Grollo et al., 2006).
THE ANTIBODY RESPONSE TO E2
Thus far, two speciﬁcities of NAb elicited in natural infection and
following vaccination with E2 derived immunogens have been
identiﬁed. Neutralizing antibodies directed toward theN-terminal
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HVR1 are immunodominant in natural infection (Kato et al.,
1993, 1994; Zibert et al., 1995). Immune serum raised to HVR1
has the ability to protect chimpanzees from experimental infec-
tion with a homologous strain of virus but are type-speciﬁc with
limited ability to neutralize immune escape variants within the
HVR1 sequence (Farci et al., 1996). As a result antibodies are
believed to have a major role in driving immune escape (Edwards
et al., 2012) and HVR1 has been proposed to be an immune
decoy (Mondelli et al., 2001). Analysis of the evolution of HCV
sequences in people infected with HCV reveals that in the absence
of NAb activity, the HVR1 sequence remains stable but rapidly
evolves under NAb pressure (Liu et al., 2010). Analysis of HVR1
speciﬁc antibody responses in HCV-infected people revealed that
those who cleared virus spontaneously were more likely to have
detectable anti-HVR1 antibodies in their serum within the ﬁrst
6 months of infection (Zibert et al., 1997) and suggests that induc-
tion of HVR1 speciﬁc antibodies in some circumstancesmay favor
viral clearance.
While HVR1 speciﬁc antibodies are largely type-speciﬁc, evi-
dence that some anti-HVR1 antibodies can be cross reactive was
obtained by vaccinating rabbits with a panel of HVR1 peptides
(Shang et al., 1999). The subsequent antibody response was able
to recognize diverse HVR1 sequences, capture HCV from patient
serum and prevent HCV binding to cells. A monoclonal antibody
speciﬁc toHVR1was also shown to be cross reactive and contained
conserved amino acids within its epitope (Li et al., 2001). While
neutralization assays were not available at the time these studies
were preformed the data suggest that HVR1 cannot be entirely
discounted as a desirable component of an HCV vaccine.
The second major speciﬁcity of NAb is directed toward
sequences involved in CD81 binding. Antibodies speciﬁc to the
CD81 binding site located on the surface of E2 are frequently
cross neutralizing due to the high degree of sequence conserva-
tion (Keck et al., 2004a; Johansson et al., 2007; Law et al., 2008).
Residues involved in binding CD81 have been mapped by per-
forming mutagenesis of E2 RBD E1/E2 and E1/E2 incorporated
into HCVpp and is summarized in Table 1. A striking feature
of these contact residues is that they are mostly aromatic and
hydrophobic amino acids and they are highly conserved between
genotypes or the substitutions are conservative; in the case of
Trp437, Phe is more frequently observed in genotypes 1b and 2-7,
and for residues Leu438 and Phe442 alternative amino acids are
I, V or M and L, M or I, respectively. The major NAb speciﬁcities
elicited toward E2 that block CD81 binding in infected humans
recognize epitopes that contain amino acids within the regions
spanning residues 411–428 and 429–448 and 523–549 and thus
directly overlap with the regions of E2 involved in CD81 binding.
These regions involved in CD81 binding overlap with neutraliza-
tion epitopes and this area represents the neutralizing face of E2
(Figures 1D,E).
A subset of antibodies directed to these regions can bind to
their epitopes in the context of synthetic peptide analogs of 411–
428 (epitope I) and 429–448 (epitope II; Figure 1A). Examples
of human monoclonal NAbs that recognize these regions include
HCV1, and95-2 (epitope I),and84-1, 84-25, 85-26 and84-27 (epi-
tope II). Antibodies that bind their epitope within the 523–549
sequence, referred to as epitope III, have also been described and
Table 1 | Residues of E2 involved in binding to CD81.
Residuea Epitopeb Alternative amino
acidsc
Reference
Trp420 I – Owsianka et al. (2006)
His421 I – Boo et al. (2012)
Trp437 II Phe Drummer et al. (2006)
Leu438 II Ile,Val, Met Drummer et al. (2006)
Leu441 II – Drummer et al. (2006)
Phe442 II Leu, Met, Ile Drummer et al. (2006)
Tyr527 III – Owsianka et al. (2006)
Trp529 III Phe Owsianka et al. (2006)
Gly530 III – Owsianka et al. (2006)
Asp535 III – Owsianka et al. (2006)
Y613RLWHYd – Roccasecca et al. (2003)
aAnalysis was performed on genotype 1a isolates. bLocation of amino acid within
an antigenic region. cAlternative amino acids observed in other isolates of HCV.
A dash indicates conserved.dData derived by replacing this region with SAASAS.
include e20, (1:7) and A8 but appear to be conformation depen-
dent (Allander et al., 2000; Johansson et al., 2007; Mancini et al.,
2009; Edwards et al., 2012). Another subset of antibodies recog-
nize discontinuous epitopes containing amino acids from one or
more of these regions and only bind folded E2 in the context of
the recombinant RBD or virion incorporated E2 such as CBH-5,
CBH-7, AR3A, AR3B, AR3C, AR3D, and Fab e137 (Hadlock et al.,
2000; Law et al., 2008; Owsianka et al., 2008; Perotti et al., 2008;
Edwards et al., 2012).
Recently, X-ray crystal structures have been determined for
neutralizing MAbs in complex with synthetic peptides analogs of
epitopes I and II and of the region encompassing epitope III in the
context of the E2 core domain. The structures reveal important
information about the conformation of these epitopes, the mode
of binding and the presence of a neutralizing face on the surface
of the E2 molecule.
EPITOPE I
The region encompassing epitope I is absent from the available
structures of the E2 core domain but two structures of MAbs
in complex with synthetic peptides reveal important structural
information about this region. The murine antibody AP33 was
ﬁrst discovered in 2001 and is a brNAb speciﬁc to epitope I
(Owsianka et al., 2001, 2005). Its binding site comprises a dis-
continuous sequence within this region and includes amino acids
Leu413,Asn415,Gly418, andTrp420with contribution byAsn417.
These amino acids are highly conserved between HCV isolates
and explain its broad cross reactivity (Tarr et al., 2006). How-
ever, this speciﬁcity of antibody does not appear to be frequently
elicited in patients with HCV as it was detected in only 2.5% of
serum samples collected from acute and chronic phases of HCV
(Tarr et al., 2007). The X-ray structure of AP33 with epitope I
reveals that the peptide forms a type 1 β-hairpin structure that
is sandwiched between the heavy and light chain of antibody.
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Hydrogen bonds formed with Asn416 and Gly418 and hydropho-
bic interactions between the side chains of Leu413 and Trp420
form the major interactions and residues from all CDR loops
except L2 are involved in binding to the peptide (Kong et al.,
2012a).
The human MAb HCV1 is speciﬁc to epitope I and is able
to neutralize genotype 1a, 1b, 2b, 3a, and 4a and binds its epi-
tope at nanomolar afﬁnity (Broering et al., 2009). Administration
of HCV1 to chimpanzees protects against HCV infection and
can be used to treat acutely infected chimpanzees (Morin et al.,
2012). As a result of these promising results, HCV1 is currently
being evaluated in clinical trials for its ability to prevent rein-
fection of the liver following transplantation. The major contact
residues are Leu413 and Trp420 (Broering et al., 2009) although
NAb escape mutants can be selected that possess the mutation
Asn415Asp/Lys. The crystal structure of HCV1 in complex with
a peptide containing HCV residues 412-423 again reveals a type
1 β hairpin structure for the peptide in contact with the heavy
chain CDR2 and CDR3 loops and the CDR3 loop of the light
chain (Kong et al., 2012b; Figure 2A). The ability of HCV1 to
mediate broad neutralization is further explained by the con-
servation of its contact residues and the solvent accessibility of
this region on the surface of E2. Additional alanine scanning
performed in the context of E1/E2 heterodimer revealed that
Asn415 andGly418were essential forHCV1 binding because these
residues are critical to the formation of the β hairpin turn and the
conformation of epitope I. Mutagenesis studies revealed that sub-
stitution of Asn415 with glutamine, glutamate or lysine preserved
the β turn architecture and maintained viral ﬁtness while signiﬁ-
cantly reducing the effectiveness of HCV1 to neutralize virus, and
thus provides a potentialmechanism for in vivo escape (Kong et al.,
2012b).
EPITOPE II
The region encompassing epitope II overlaps extensively with
key CD81 contact residues (Drummer et al., 2006) and brNAb
that bind this region have only recently been described (Law et al.,
2008; Keck et al., 2012). Antibodies to this region are particu-
larly interesting as passage of cell culture derived virus with a
neutralizing amount of antibody fails to select for escape mutants
suggesting that ﬁt viruseswith escapemutations cannot be selected
(Keck et al., 2012). Two antibodies, 84-1 and 84-27 recognize a
synthetic peptide analog and their crystal structures have been
determined (Krey et al., 2013). Inboth cases, the peptide adopts the
sameconformation suggesting it reﬂects that observed in thenative
structure of E2, and not an induced ﬁt conferred by the antibody.
The peptide adopts a 1.5 α-helical turn spanning Trp437-Phe442
with Tyr438-Lys446 adopting an extended conformation. In the
case of 84-1, E2 amino acids Leu441 and Phe442 make exten-
sive hydrophobic contact with the antibody heavy chain that is
further stabilized by a hydrogen bonding network that includes
Lys446 and Trp443 (Figure 2B). Analysis of the Los Alamos
HCV database revealed that Thr435, Gly436, Ala439, Leu441, and
Tyr443 are highly conserved while Gln444 and His445 are less
conserved. The key contact residue Phe442, conserved in 60% of
sequences, can only be replaced with bulky hydrophobic amino
acids. The conservation of Leu441 and Phe442 suggest a strict
structural constraint at this position to maintain glycoprotein
function, possibly explaining why neutralization escape mutants
could not be selected with these antibodies. This immunogenic
domain of E2 overlaps with HVR3 and suggests that the region
is under immune selection pressure suggesting that some anti-
bodies to this region, elicited in natural infection, may not be
able to prevent immune escape in vivo, as was observed for 84-1
in vitro.
EPITOPE III
The E2 structure provided by Kong et al. (2013) was obtained
by co-crystallization of E2 with neutralizing human MAb AR3C
whose epitope contains residues from epitope III at positions 530,
535, 538, and 540 and one residue from epitope I at position 424
(Law et al., 2008; Figure 2C). In the co-crystal structure, AR3C
buries 828 Å of E2 surface area and 161 Å of E2 glycan surface
area and additional points of contact with E2 were revealed (Kong
et al., 2013). 86% of the buried E2 surface comprises residues that
are 80–100% conserved across all E2 sequences. The epitope of
AR3Ccomprisesmost of the front layer, someamino acids between
421–446 and theCD81binding loop. Themajority of contactswith
E2 are mediated by the heavy chain CDR3 (44% of total buried
surface). The binding site for AR3C overlaps directly with the
CD81 binding site and is a surface exposed, hydrophobic region,
relatively unobscured by carbohydrate (Kong et al., 2013). A vac-
cine with the ability to elicit such antibody speciﬁcities is therefore
highly desirable as they are likely to have broad neutralization
potential.
WHY HAVE VACCINES FOR HCV NOT BEEN DEVELOPED?
Unlike its ﬂavivirus counterparts, expression of the HCV glyco-
proteins E1 and E2 does not result in the secretion of subviral
particles, the component of all ﬂaviviral vaccines. The ability to
cultureHCVwas developed in 2005 but remains limited to a hand-
ful of isolates and titres remain low making large-scale production
of an inactivated vaccine unlikely. Nevertheless, Akazawa et al.
(2013) have successfully demonstrated that sufﬁcient HCVcc can
be produced from cell culture and the inactivated HCVcc were
used to immunize mice. The antibodies were able to neutralize
genotypes 1a, 1b, and 2a viruses and prevented the infection
of human liver transplanted onto uPa-SCID mice but only at
the lowest homologous challenge dose of virus (Akazawa et al.,
2013). In vivo heterologous neutralization was not examined. The
immune serum from mice vaccinated with the inactivated HCVcc
particles were more efﬁcient at neutralizing homologous virus
than immune serum from mice vaccinated with recombinant E2
alone or recombinant E1 and E2, suggesting intact particles are
likely to be more immunogenic than the isolated recombinant
glycoproteins.
Only one HCV vaccine candidate aimed at eliciting NAb has
been tested in humans. The vaccine initially developed by Chiron
Corporation was based on recombinant HCV E1 and E2 glyco-
proteins puriﬁed from mammalian cells as a non-disulﬁde linked
heterodimer. In preclinical studies conducted in chimpanzees,
the vaccine induced high titres of E1 and E2 speciﬁc antibodies
and prevented ﬁve chimpanzees from becoming infected with a
homologous challenge of virus and protection correlated with the
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FIGURE 2 | Structure of human MAbs in complex with their
epitopes. (A) Structure of the paratope of MAb HCV1 in complex with
synthetic peptide spanning residues 412–423 within E2 epitope I (pink).
Amino acids side chains within the paratope in contact with the
antibody epitope are shown as sticks. The antibody heavy chain is
colored green and the light chain is in blue and major contact residues
within the peptide shown as purple sticks. (B) Structure of the paratope
of HC84-1 with its epitope spanning 435–446. Labeled as for A.
(C) Structure of the E2 core domain in complex with neutralizing
antibody AR3C. E2 is colored in red with the side chains of the amino
acid in contact with the antibody shown as sticks. Heavy chain is green
and light chain is blue.
presence of high titre anti-E2 antibodies (Choo et al., 1994). Chal-
lenge of the chimpanzees with a closely related heterologous virus
strain resulted in infection in all cases; all but one vaccinee did not
progress to chronic infection, suggesting the vaccine does induce a
degree of protective but not sterilizing immunity (Houghton and
Abrignani, 2005).
The recombinant E1/E2 vaccine was trialed in healthy human
volunteers and adjuvanted with MF59. The initial results of this
trial revealed that 15/41 subjects had antibody reactive to E1 region
313-327, 21/41 subjects had anti-HVR1 speciﬁc antibodies, 23/41
had epitope I reactive antibodies, and 13/41 had epitope II reactive
antibodies, where reactivity was deﬁned as a greater than twofold
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higher optical density compared to pre-immune or placebo sam-
ples (Ray et al., 2010). Nine, 11, 10, and 5 samples with E1,
HVR1, epitope I, or epitope II reactive antibodies, respectively,
neutralized virus, although it is not entirely clear what level of
neutralization was achieved. The higher proportions of epitope I
reactive antibodies compared to that reported in natural infection
is a promising outcome of this vaccine trial if it can be corre-
lated with an increase in cross-neutralizing activity in these sera.
In a subsequent study, using a more extensive panel of HCVcc
from each of the 7 genotypes revealed that of the three subjects
tested, one subject elicited sera with the ability to mediate ∼25 to
80% neutralization of HCVcc at a 1/50 dilution of serum with the
highest neutralization observed against genotype 6 and the low-
est to genotype 7 (Law et al., 2013). These results should provide
encouragement to the ﬁeld of vaccine research that cross neu-
tralizing antibodies can be elicited by recombinant E1/E2 based
vaccines andwarrant further study. Amajor limitation of the stud-
ies described above are the relatively low titres of NAbs elicited,
their limited cross neutralizing potential, and their modest level of
neutralization. A number of mechanisms whereby the HCV gly-
coproteins can evade the immune response have been illuminated
and suggest that alternative approaches to vaccine design may be
required, similar to the approach currently being used for HIV
and inﬂuenza (Nabel, 2012).
INTERFERENCE OF NEUTRALIZATION BY VARIABLE REGIONS
OF E2
The three variable regions of E2 have been implicated in immune
evasion by HCV. HVR1 contains the epitopes of NAbs that
block E2 binding to SR-B1 but not to CD81 (Sabo et al., 2011).
Instead, HVR1 antibodies can allosterically shield the CD81
binding site and conserved NAb epitopes therein providing an
additional mechanism of neutralization escape (Bankwitz et al.,
2010). Roccasecca et al. (2003) examined the effect of chimeriza-
tion of HVR1 and HVR2 in closely related strains of HCV and
the effect of HVR1 deletion on CD81 binding. The efﬁciency of
CD81 binding was found to be strain dependent and deletion
of HVR1 enhanced CD81 binding when performed in the con-
text of recombinant E2 RBD and recombinant CD81 LEL and
RBD binding to CD81 on the surface of Molt-4 cells suggest-
ing that HVR1 may at least partially occlude the CD81 binding
site. When HVR1 or HVR2 was swapped between E2 strains,
no difference in CD81 binding was observed. However, when
both HVR1 and HVR2 of strain H were interchanged with
those of the N2 strain, a fourfold reduction in CD81 binding
was observed. The reciprocal chimera resulted in an increase
in CD81 binding (Roccasecca et al., 2003). These results suggest
that CD81 binding is modulated by the presence of HVR1 and
the sequence of HVR2 implying that these regions are ﬂexible
surface exposed domains that may provide a means to shield
the underlying CD81 binding site, occluding it from immune
surveillance.
The effect of the variable regions on CD81 binding was fur-
ther explored by McCaffrey et al. (2007). In this study, HVR1,
HVR2, and the igVR were deleted from the E2 RBD individually
and in combination to identify the ﬁrst E2 core domain (McCaf-
frey et al., 2007). While all three variable regions could be deleted
without affecting CD81 binding, deletion of two of the three vari-
able regionsmodulatedCD81binding function. DeletionofHVR2
and the igVR, or HVR1 and the igVR resulted in similar levels of
CD81 binding as wild-type E2 RBD. However, deletion of HVR1
and HVR2 from the E2 RBD resulted in an approximately 50%
reduction in CD81 binding. These results indicate that the pres-
ence of the igVR interferes with CD81 binding function when
HVR1 and HVR2 is absent and point to a functional interaction
between the igVR and HVR1 and/or HVR2 such that the CD81
binding site is properly formed or becomes fully accessible to the
receptor. The available crystal structures of E2 are of a monomer.
Absent from these structures is information about the E2 stem
region, E1 and detailed structural information about HVR1, epi-
tope I and HVR2. It is likely that the structure of intact E2 on the
surface of a virion as a heterodimer with E1 differs from the struc-
tures of the E2 core thus far available. Indeed, all fusion proteins
exist as either dimers of heterodimers or trimers of heterodimers
and this is likely to be the case for HCV as well. Thus it is pos-
sible that in these higher order structures of virion incorporated
E2, the variable regions may form additional contacts with the
opposing E1 or E2 protomers providing additional mechanisms
whereby HVR1, HVR2, and the igVR can interfere with antibody
recognition and CD81 binding.
Finally, the reason why HVR2 and igVR sequences evolve
rapidly in infected patients remains unresolved. Neither region
has been implicated as being targets of the antibody response sug-
gesting that a direct mechanism of immune evasion is not likely.
However, it is possible that the sequence of HVR2 and the igVR
could alter their ability to shield the E2 core from neutralizing
antibodies or alters E1/E2 conformation while retaining function
providing an allosteric mechanism of immune escape and require
further studies.
NEUTRALIZING AND NON-NEUTRALIZING ANTIBODIES
A subset of epitope II directed non-neutralizing antibodies have
been reported to interfere with the capacity of epitope I anti-
bodies to neutralize virus (Zhang et al., 2009) while other epitope
II-directed NAbs act cooperatively with epitope I speciﬁc NAbs
(Keck et al., 2012, 2013). The ability of neutralizing antibodies
directed toward epitope II to prevent neutralization escape sug-
gests that they are a highly desirable component of the antibody
response to any HCV vaccine but it is not clear what propor-
tions of antibodies speciﬁc to epitope II have neutralizing/non-
neutralizing activity innatural infectionor in vaccination. Analysis
of the ﬁne speciﬁcity of the antibody response in natural infec-
tion is necessary to dissect these effects and examine their
neutralization capacity.
GLYCOSYLATION OF E2 AND ITS EFFECT ON
NEUTRALIZATION
E2 contains 11 sites for N-linked glycosylation that are largely con-
served in different HCV isolates suggesting they play important
roles in glycoprotein structure and function. Helle et al. (2007)
found that Asn417, Asn532, and Asn623 obscured E2 from CD81
binding and interfered with the ability of antibody to neutralize
virus in the context of HCVpp. InHCVcc, an additional two glyco-
sylation sites impacted on neutralization sensitivity at Asn423 and
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Asn446 (Helle et al., 2010). All ﬁve glycosylation sites are directly
adjacent toCD81 contact residues suggesting that theymay restrict
the ability to elicit NAbs toward these CD81 binding regions or
impact on accessibility of underlying epitopes to antibody neu-
tralization. In genotype 3a viruses, an additional glycosylation
site at position 495 reduces the sensitivity of HCV to neutral-
ization using pooled HCV positive immune serum, and suggests
that in some viruses, additional mechanisms of glycan mediated
immune escape may evolve (Anjum et al., 2013). The structure of
E2 indicates that 7/11 glycans shield the neutralizing face of the E2
core domain conﬁrming that glycans potentially have the ability
to restrict the generation of antibodies to these regions in natu-
ral infection and vaccination and /or restrict antibody access to
epitopes.
IMPACT ON VACCINE DESIGN
While recombinant E2 provides an obvious vaccine candidate as
it can be produced in large amounts, the above information sug-
gests its use requires caution. Variable regions within E2 have the
potential to occlude the underlying CD81 binding site, HVR1 is
immunodominant and drives immune escape and the extensive
glycan shield protects the neutralizing face of E2. In addition,
the use of isolated E2 may promote the elicitation of antibodies
to the non-neutralizing face highly exposed in monomeric E2.
The lack of neutralizing ability of antibodies directed to this non-
neutralizing face of E2 is likely to be explained by its occlusion
in virion incorporated E1/E2 heterodimers or its occlusion in the
higher order arrangement of E1/E2 heterodimers in the virion,
e.g., dimers or trimers of heterodimers. These caveats on the
use of E2 as an immunogen are highly reminiscent of the HIV-
1 gp120 monomer that contains ﬁve variable regions, extensive
glycan shielding, and an immunodominant non-neutralizing face.
The low frequency of antibodies elicited to epitope I in natural
infection suggest it is subdominant and engineering of the E2
protein may be required to increase the titre of antibodies speciﬁc
to this region in vaccine candidates. Similar studies investigating
the titre and prevalence of antibodies directed toward epitopes II
or III are required to understand whether these speciﬁcities are
elicited in native forms of E2 or whether reengineering of E2 is
required to make these epitopes immunodominant. Finally, key to
successful vaccine design is an understanding of the correlates of
protective immunity. Future studies aimed at delineating the ﬁne
speciﬁcity of the antibody response in people who successfully
clear their HCV infection will provide essential information to
guide the rational design of an HCV vaccine.
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